Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study

Background Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was under...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMC neurology Ročník 17; číslo 1; s. 171 - 5
Hlavní autoři:	Zecca, Chiara, Disanto, Giulio, Mühl, Sarah, Gobbi, Claudio
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 04.09.2017 BMC
Témata:	Adherence Adjuvants, Immunologic - administration & dosage Adult Autoinjector Demyelinating diseases Disabled Persons Female Humans Injections, Subcutaneous Interferon beta-1a - administration & dosage Male Medication Adherence - statistics & numerical data Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurochemistry Neurologists Neurology Neurosurgery Patient Compliance RebiSmart Research Article sc IFN β-1a Self Administration Self Medication - instrumentation Self Report Subcutaneous interferon β-1a Surveys and Questionnaires Adherence Multiple sclerosis Self-reported adherence Subjective adherence RebiSmart Objective adherence sc IFN β-1a Patient adherence Subcutaneous interferon β-1a Autoinjector
ISSN:	1471-2377, 1471-2377
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!